What the business is, and whether it's a good one at a fair price.
Sells fast-moving consumer healthcare brands in India across three therapeutic areas: allergy (Allegra, Avil), pain (Combiflam), and vitamins/minerals/supplements (DePURA). The company was carved out of Sanofi's prescription pharma business and is positioning itself as a brand-equity-driven OTC player under global parent Opella, whose other shareholder is CD&R. Domestic sales contribute the bulk of revenue, with a smaller export book that fell 9% in Q2 FY26 on a high base; total Q2 FY26 revenue was Rs 2,357 mn (+7% YoY) and H1 FY26 revenue was Rs 4,649 mn (+18% YoY). Brands hold top-five positions in their categories—Avil is #1 by volume, Allegra #3 by value, Combiflam #5, and DePURA top-5 in Vitamin D. Distribution is being deepened via direct retail coverage, with the company planning to roughly 2X its direct retail footprint and add 50,000 healthcare professionals via digital in 2026. Production is almost entirely local, and the model is shifting from prescription-style doctor dependence toward consumer self-choice, supported by doctor recommendations and consumer education.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Not enough history to assess.How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from SANOFI CONS HEALTHC IND L's filed financials and exchange disclosures
SANOFI CONS HEALTHC IND L is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol SANOFICONR.
Yes. Over the trailing twelve months SANOFI CONS HEALTHC IND L reported a net profit of ₹266 Cr on revenue of ₹950 Cr.
Effectively yes. It holds ₹490 Cr more cash than debt.
On trailing P/E, SANOFI CONS HEALTHC IND L ranks 96 of 169 in Pharmaceuticals — cheaper than 44% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session SANOFI CONS HEALTHC IND L moves 0.92% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by SANOFI CONS HEALTHC IND L appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
